Abstract Library

#4089 Peptide receptor radionuclide therapy is effective for hormonal control of carcinoid syndrome

Introduction: Carcinoid syndrome (CS) is the most common functioning syndrome in neuroendocrine tumors (NET) and manifests in symptoms of flushing, diarrhea and fibrosis. Serotonin, a tryptophan metabolite, is considered the principal hormonal mediator of CS. Peptide receptor radionuclide therapy (PRRT) has established antiproliferative effects in NET, but the clinical and biochemical response to PRRT in CS patients is unknown.

Conference:

Presenting Author: Maas C

Authors: Maas C, Mulders M, Mirzaian M, van den Berg S, Brabander T,

Keywords: carcinoid syndrome, neuroendocrine tumor, peptide receptor radionuclide therapy, serotonin,

#4017 Serum 5-hydroxyindoleacetic acid is equivalent to 24-hour urinary 5-hydroxyindoleacetic acid for the diagnosis of carcinoid syndrome

Introduction: Neuroendocrine tumors (NET) are characterized by their ability to secrete amines and peptides. Overproduction of serotonin results in the carcinoid syndrome (CS), present in approximately 20% of all NET patients. Measuring the main metabolite of serotonin, 5-hydroxyindoleacetic acid (5-HIAA), in 24-hour urine is frequently used for the diagnosis and follow-up of CS patients. However, these measurements are prone to sampling error and may be troublesome for patients. Serum 5-HIAA measurements might be a more reliable and convenient alternative in the diagnosis of CS.

Conference:

Presenting Author:

Authors: Kerolles M, Mulders M, Mirzaian M, van den Berg S, Feelders R,

Keywords: 5-hiaa, carcinoid syndrome, neuroendocrine tumor, biomarker,